View in EDS

A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Saved in:
Bibliographic Details
Title: A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
Authors: Garrigós, L.1,2 (AUTHOR), Ruiz-Borrego, M.3 (AUTHOR), Pérez-García, J.M.1,4 (AUTHOR), Guerrero-Zotano, A.4,5 (AUTHOR), Cortés-Salgado, A.4,6 (AUTHOR), Kuemmel, S.7 (AUTHOR), Colleoni, M.8 (AUTHOR), Reboredo-Rendo, C.9 (AUTHOR), Bermejo, B.10,11 (AUTHOR), Blancas, I.12,13,14 (AUTHOR), Gavila, J.5 (AUTHOR), Fabi, A.15 (AUTHOR), Morales, C.16 (AUTHOR), Stradella, A.17 (AUTHOR), Carañana, V.18 (AUTHOR), Martínez-de Dueñas, E.19 (AUTHOR), Albacar, C.20 (AUTHOR), Ballesteros-Cidras, O.4 (AUTHOR), Martrat, G.4 (AUTHOR), Iacobucci, S.4 (AUTHOR)
Source: Annals of Oncology. Jun2026, Vol. 37 Issue 6, p837-848. 12p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2026.01.013